A Multicenter, Randomized, Open-label Study to Compare the Tolerability Between Rivastigmine Patch Monotherapy and Combination Therapy With Memantine in Patients With Alzheimer's Disease.

Trial Profile

A Multicenter, Randomized, Open-label Study to Compare the Tolerability Between Rivastigmine Patch Monotherapy and Combination Therapy With Memantine in Patients With Alzheimer's Disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Rivastigmine (Primary) ; Memantine
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacogenomic
  • Acronyms EXPECT
  • Most Recent Events

    • 19 Jul 2012 Efficacy results presented at the 2012 International Conference on Alzheimer's Disease.
    • 12 May 2011 Primary endpoint "retention rate" has been met, according to results published in Current Medical Research and Opinion.
    • 12 May 2011 Results published in Current Medical Research and Opinion.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top